OncoIndustry
Replimune Announces Favorable Outcome of FDA’s Advisory Committee Meeting
Replimune

Replimune Announces Favorable Outcome of FDA’s Advisory Committee Meeting

Replimune, shared on LinkedIn:

“Yesterday, we announced the favorable outcome of the FDA’s Cellular, Tissue, and Gene Therapies Advisory Committee Meeting for RP1 in Advanced Melanoma.

Read more.”

Replimune

advanced melanoma cancer cancer immunotherapy Cellular Tissue and Gene Therapies Advisory Committee FDA gene therapy immunotherapy Melanoma OncoDaily Oncology oncolytic immunotherapy Replimune RP1 skin cancer U.S. Food and Drug Administration